{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:27:56Z","timestamp":1792787276338,"version":"4.5.0"},"reference-count":33,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"unspecified","delay-in-days":20,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Otsuka Pharmaceutical Development & Commercialization","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"https:\/\/ror.org\/001nxvg84","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,8,27]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess patient characteristics, treatment patterns and clinical outcomes of immunoglobulin A nephropathy (IgAN) in China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Regional electronic health records database from Yinzhou District of Ningbo City, China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>A total of 978 adult patients with biopsy-proven primary IgAN diagnosed between 2015 and 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcome measures<\/jats:title>\n                    <jats:p>Baseline characteristics, treatment patterns before and after renal biopsy, and temporal treatment trends were assessed. Clinical outcomes included composite renal events and estimated glomerular filtration rate (eGFR) decline trajectories according to proteinuria levels at biopsy and during follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Most patients were diagnosed at early chronic kidney disease stages (70.1% stage I\u2013II) but frequently exhibited hypertension (55.0%) and advanced pathological features, with 85.9% classified as Lee grade III\u2013V and 77.8%\u201398.9% showing M1, E1 or S1 lesions. At biopsy, 65.6% had proteinuria &gt;0.5\u2009g\/day. Over a median follow-up of 3 years, 6.7% experienced composite renal events, while 58.2% maintained proteinuria &gt;0.5\u2009g\/day. Renin\u2013angiotensin\u2013aldosterone system inhibitors were widely prescribed (91.5%), with increasing use of sodium-glucose cotransporter-2 inhibitors and non-steroidal immunosuppressants and declining corticosteroid use over time. After adjustment for key demographic and clinical factors, persistent proteinuria was associated with higher renal risk and faster eGFR decline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Despite early diagnosis and strong guideline adherence, persistent proteinuria and adverse outcomes remain common, underscoring the need for more effective therapies in IgAN.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2026-120567","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T14:25:42Z","timestamp":1790000742000},"page":"e120567","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Patient characteristics, treatment patterns and clinical outcomes of immunoglobulin a nephropathy (IgAN) in China: a retrospective cohort study"],"prefix":"10.1136","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1349-4807","authenticated-orcid":false,"given":"Ziqi","family":"Pan","sequence":"first","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China"},{"name":"Key Laboratory of Epidemiology of Major Diseases (Peking University), Ministry of Education, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Shen","sequence":"additional","affiliation":[{"name":"Yinzhou District Center for Disease Control and Prevention, Ningbo, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yexiang","family":"Sun","sequence":"additional","affiliation":[{"name":"Yinzhou District Center for Disease Control and Prevention, Ningbo, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhike","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China"},{"name":"Key Laboratory of Epidemiology of Major Diseases (Peking University), Ministry of Education, Beijing, China"},{"name":"Peking university - Yinzhou Regional joint institute for Advanced Medical Intelligence and Digital health, Ningbo, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zuo","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqin","family":"Jiang","sequence":"additional","affiliation":[{"name":"Yinzhou District Center for Disease Control and Prevention, Ningbo, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7252-5349","authenticated-orcid":false,"given":"Siyan","family":"Zhan","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China"},{"name":"Key Laboratory of Epidemiology of Major Diseases (Peking University), Ministry of Education, Beijing, China"},{"name":"Peking university - Yinzhou Regional joint institute for Advanced Medical Intelligence and Digital health, Ningbo, China"},{"name":"Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, China"},{"name":"Center for Intelligent Public Health, Institute for Artificial Intelligence, Peking University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"2026092107250903000_16.9.e120567.1","doi-asserted-by":"crossref","first-page":"16001","DOI":"10.1038\/nrdp.2016.1","article-title":"IgA nephropathy","volume":"2","author":"Lai","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"2026092107250903000_16.9.e120567.2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ekir.2024.11.510","article-title":"WCN25-52 Epidemiology of immunoglobulin a nephropathy (IgAN) and occurrence of proteinuria in China: evidence from systematic review and meta-analysis","volume":"10","author":"Chen","year":"2025","journal-title":"Kidney Int Rep"},{"key":"2026092107250903000_16.9.e120567.3","doi-asserted-by":"crossref","first-page":"S126","DOI":"10.1016\/j.jval.2021.11.605","article-title":"POSA204 Disease Burden of Iga Nephropathy in China","volume":"25","author":"Du","year":"2022","journal-title":"Value in Health"},{"key":"2026092107250903000_16.9.e120567.4","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr527"},{"key":"2026092107250903000_16.9.e120567.5","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.01990213"},{"key":"2026092107250903000_16.9.e120567.6","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1053\/j.ajkd.2023.12.016","article-title":"Time-Varying Proteinuria and Progression of IgA Nephropathy: A Cohort Study","volume":"84","author":"Tang","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"2026092107250903000_16.9.e120567.7","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1093\/ndt\/gfae252","article-title":"Long-term outcomes of IgA nephropathy in China","volume":"40","author":"Shen","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"2026092107250903000_16.9.e120567.8","doi-asserted-by":"crossref","DOI":"10.1186\/s12882-025-04709-9","article-title":"Treatment patterns, clinical outcomes, and economic burden among patients with immunoglobulin A nephropathy (IgAN) in China","volume":"27","author":"Liu","year":"2026","journal-title":"BMC Nephrol"},{"key":"2026092107250903000_16.9.e120567.9","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.0000000000000135"},{"key":"2026092107250903000_16.9.e120567.10","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1111\/imj.16539","article-title":"Immunoglobulin A nephropathy is not what it used to be!","volume":"54","author":"Swaminathan","year":"2024","journal-title":"Intern Med J"},{"key":"2026092107250903000_16.9.e120567.11","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.12-6-s27"},{"key":"2026092107250903000_16.9.e120567.12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00926.x"},{"key":"2026092107250903000_16.9.e120567.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2025.04.004"},{"key":"2026092107250903000_16.9.e120567.14","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2007050526"},{"key":"2026092107250903000_16.9.e120567.15","doi-asserted-by":"crossref","DOI":"10.1186\/s12882-024-03555-5","article-title":"Review on epidemiology, disease burden, and treatment patterns of IgA nephropathy in select APAC countries","volume":"25","author":"Zaidi","year":"2024","journal-title":"BMC Nephrol"},{"key":"2026092107250903000_16.9.e120567.16","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-030102","article-title":"Using electronic health record data to establish a chronic kidney disease surveillance system in China: protocol for the China Kidney Disease Network (CK-NET)-Yinzhou Study","volume":"9","author":"Wang","year":"2019","journal-title":"BMJ Open"},{"key":"2026092107250903000_16.9.e120567.17","doi-asserted-by":"publisher","DOI":"10.26599\/1671-5411.2025.01.008"},{"key":"2026092107250903000_16.9.e120567.18","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2015.241"},{"key":"2026092107250903000_16.9.e120567.19","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000368914","article-title":"Reasons for discontinuation of lipid-lowering medications in patients with chronic kidney disease","volume":"4","author":"Morrison","year":"2014","journal-title":"Cardiorenal Med"},{"key":"2026092107250903000_16.9.e120567.20","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1093\/ndt\/gfac004","article-title":"Rapidly progressive IgA nephropathy: clinicopathological characteristics and outcomes assessed according to the revised definition of the KDIGO 2021 Guideline","volume":"37","author":"Yu","year":"2022","journal-title":"Nephrol Dial Transplant"},{"key":"2026092107250903000_16.9.e120567.21","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1159\/000525001","article-title":"Long-Term Outcomes of Patients with IgA Nephropathy Categorized by the International IgAN Risk Prediction Tool and by the Degree of Hematuria at Diagnosis","volume":"146","author":"Ebbestad","year":"2022","journal-title":"Nephron"},{"key":"2026092107250903000_16.9.e120567.22","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.20233411S1995a","article-title":"Rate of Loss of eGFR and Time-Averaged Proteinuria in IgA Nephropathy (IgAN) Patients Progressing from Early-Stage Disease to Kidney Failure","volume":"34","author":"Pitcher","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"2026092107250903000_16.9.e120567.23","first-page":"918","article-title":"Clinical practice guidelines for adult patients with IgA nephropathy and IgA vasculitis-associated nephritis in China (2025) [Article in Chinese]","volume":"64","author":"Li","year":"2025","journal-title":"Chin J Intern Med"},{"key":"2026092107250903000_16.9.e120567.24","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1053\/j.ajkd.2019.02.016","article-title":"Prediction and Risk Stratification of Kidney Outcomes in IgA Nephropathy","volume":"74","author":"Chen","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"2026092107250903000_16.9.e120567.25","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/ndt\/gfad139","article-title":"Intensive blood pressure control and the progression of IgA nephropathy: a cohort study using marginal structural models","volume":"39","author":"Tang","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"2026092107250903000_16.9.e120567.26","first-page":"1","article-title":"Chinese expert consensus on the management and treatment of primary IgA nephropathy [Article in Chinese]","volume":"13","year":"2024","journal-title":"Chin J"},{"key":"2026092107250903000_16.9.e120567.27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1415463"},{"key":"2026092107250903000_16.9.e120567.28","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.5368"},{"key":"2026092107250903000_16.9.e120567.29","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.ekir.2017.02.003","article-title":"Severe Adverse Effects Associated With Corticosteroid Treatment in Patients With IgA Nephropathy","volume":"2","author":"Cai","year":"2017","journal-title":"Kidney Int Rep"},{"key":"2026092107250903000_16.9.e120567.30","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2019.11.008"},{"key":"2026092107250903000_16.9.e120567.31","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-67910-w","article-title":"Spectrum of biopsy proven renal diseases in Central China: a 10-year retrospective study based on 34,630 cases","volume":"10","author":"Hu","year":"2020","journal-title":"Sci Rep"},{"key":"2026092107250903000_16.9.e120567.32","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2215\/CJN.0000000952","article-title":"The Association between Low-Grade Proteinuria and Adverse Kidney Outcomes in IgA Nephropathy: A Systematic Review and Meta-Analysis","volume":"21","author":"Yamaguchi","year":"2026","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026092107250903000_16.9.e120567.33","doi-asserted-by":"crossref","DOI":"10.1186\/s12882-020-01982-8","article-title":"Predictive factors of rapid linear renal progression and mortality in patients with chronic kidney disease","volume":"21","author":"Ali","year":"2020","journal-title":"BMC Nephrol"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2026-120567","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T14:25:46Z","timestamp":1790000746000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2026-120567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":33,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,21]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/bmjopen-2026-120567"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2026-120567","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}